Emerging Therapeutic Options for the Management of COPD

Department of Pharmacy Practice, School of Pharmacy, Northeastern University, Boston, MA, USA.
Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine 04/2013; 7:7-15. DOI: 10.4137/CCRPM.S8140
Source: PubMed

ABSTRACT Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide and is projected to be the third by 2020. COPD is characterized by chronic airflow limitation caused by airway inflammation and parenchymal destruction that is usually progressive. Inhaled bronchodilators continue to be the mainstay of the current management of COPD. Safety and efficacy data of the recently approved medications including aclidinium, glycopyrronium, roflumilast, and indacaterol are reviewed here.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Chronic obstructive pulmonary disease (COPD) is increasing worldwide and is predicted to become the third most frequent cause of death by 2030. Muscarinic receptor antagonists, alone or in combination with long-acting β2-agonists, are frequently used for COPD therapy. Aclidinium bromide is a novel muscarinic receptor antagonist, and clinical studies indicate that its metabolism is more rapid than that of other muscarinic receptor inhibitors, so systemic side effects are expected to occur less frequently. Aclidinium bromide is well tolerated, and when compared with other muscarinic receptor antagonists, the drug achieves better control of lung function, especially night-time symptoms in COPD patients. This review summarizes the safety profile and side effects reported by recent clinical studies using aclidinium bromide alone.
    Therapeutics and Clinical Risk Management 06/2014; 10:449-53. DOI:10.2147/TCRM.S39710 · 1.47 Impact Factor


1 Download
Available from